BR112018016912A2 - novo antígeno para uso na vacina contra malária - Google Patents
novo antígeno para uso na vacina contra maláriaInfo
- Publication number
- BR112018016912A2 BR112018016912A2 BR112018016912A BR112018016912A BR112018016912A2 BR 112018016912 A2 BR112018016912 A2 BR 112018016912A2 BR 112018016912 A BR112018016912 A BR 112018016912A BR 112018016912 A BR112018016912 A BR 112018016912A BR 112018016912 A2 BR112018016912 A2 BR 112018016912A2
- Authority
- BR
- Brazil
- Prior art keywords
- antigens
- malaria vaccine
- new antigen
- malaria
- vaccine
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 5
- 102000036639 antigens Human genes 0.000 title abstract 5
- 108091007433 antigens Proteins 0.000 title abstract 5
- 229940124735 malaria vaccine Drugs 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 208000037369 susceptibility to malaria Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a presente invenção provê polipeptídeos úteis como antígenos expressos no estágio pré-eritrocítico do parasita da malária. os antígenos podem ser empregados para induzir resposta imune e proteção estéril contra malária em um mamífero por administração de antígenos nas formulações de vacina ou expressando os antígenos no dna ou outros sistemas de expressão de proteína recombinante liberados como uma formulação de vacina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662296464P | 2016-02-17 | 2016-02-17 | |
| PCT/US2017/017722 WO2017142843A1 (en) | 2016-02-17 | 2017-02-13 | Novel antigen for use in malaria vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018016912A2 true BR112018016912A2 (pt) | 2018-12-26 |
Family
ID=59559460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018016912A BR112018016912A2 (pt) | 2016-02-17 | 2017-02-13 | novo antígeno para uso na vacina contra malária |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10195260B2 (pt) |
| EP (1) | EP3416681A4 (pt) |
| JP (2) | JP7261013B2 (pt) |
| KR (1) | KR20180108754A (pt) |
| CN (1) | CN109069607A (pt) |
| AU (1) | AU2017219613B2 (pt) |
| BR (1) | BR112018016912A2 (pt) |
| CA (1) | CA3014196A1 (pt) |
| WO (1) | WO2017142843A1 (pt) |
| ZA (1) | ZA201805547B (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3416681A4 (en) | 2016-02-17 | 2020-03-18 | Camris International, Inc. | NOVEL ANTIGEN FOR USE IN ANTI-MALARIA VACCINE |
| CN110703326B (zh) * | 2019-10-11 | 2021-07-16 | 中国石油化工股份有限公司 | 一种基于中小偏移距道集的fvo反演方法 |
| GB2615470A (en) * | 2020-10-20 | 2023-08-09 | Longhorn Vaccines & Diagnostics Llc | Immunogenic antigens |
| WO2024063788A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
| WO2024064934A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of plasmodium csp antigens and related methods |
| WO2024064931A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of liver stage antigens and related methods |
| WO2024063789A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101863970B (zh) * | 2010-05-18 | 2012-09-12 | 吉林大学 | 一种可抑制恶性疟原虫侵入的抗Pf332-DBL区单克隆抗体 |
| US9884101B2 (en) | 2010-11-09 | 2018-02-06 | The Walter And Eliza Hall Institute For Medical Research | Treatment and prevention of malaria |
| WO2013108272A2 (en) * | 2012-01-20 | 2013-07-25 | International Centre For Genetic Engineering And Biotechnology | Blood stage malaria vaccine |
| GB201318084D0 (en) * | 2013-10-11 | 2013-11-27 | Isis Innovation | Malaria vaccination |
| EP3416681A4 (en) | 2016-02-17 | 2020-03-18 | Camris International, Inc. | NOVEL ANTIGEN FOR USE IN ANTI-MALARIA VACCINE |
-
2017
- 2017-02-13 EP EP17753691.9A patent/EP3416681A4/en active Pending
- 2017-02-13 JP JP2018544178A patent/JP7261013B2/ja active Active
- 2017-02-13 CN CN201780012190.0A patent/CN109069607A/zh active Pending
- 2017-02-13 CA CA3014196A patent/CA3014196A1/en active Pending
- 2017-02-13 KR KR1020187024980A patent/KR20180108754A/ko unknown
- 2017-02-13 WO PCT/US2017/017722 patent/WO2017142843A1/en active Application Filing
- 2017-02-13 US US15/431,609 patent/US10195260B2/en active Active
- 2017-02-13 BR BR112018016912A patent/BR112018016912A2/pt unknown
- 2017-02-13 AU AU2017219613A patent/AU2017219613B2/en active Active
-
2018
- 2018-08-20 ZA ZA2018/05547A patent/ZA201805547B/en unknown
- 2018-12-21 US US16/230,512 patent/US11793868B2/en active Active
-
2021
- 2021-12-10 JP JP2021200524A patent/JP2022037078A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10195260B2 (en) | 2019-02-05 |
| US20170232091A1 (en) | 2017-08-17 |
| ZA201805547B (en) | 2023-01-25 |
| US11793868B2 (en) | 2023-10-24 |
| JP2019505560A (ja) | 2019-02-28 |
| JP2022037078A (ja) | 2022-03-08 |
| US20190117752A1 (en) | 2019-04-25 |
| CA3014196A1 (en) | 2017-08-24 |
| WO2017142843A1 (en) | 2017-08-24 |
| AU2017219613B2 (en) | 2022-04-07 |
| JP7261013B2 (ja) | 2023-04-19 |
| KR20180108754A (ko) | 2018-10-04 |
| EP3416681A1 (en) | 2018-12-26 |
| AU2017219613A1 (en) | 2018-08-30 |
| WO2017142843A8 (en) | 2018-09-07 |
| EP3416681A4 (en) | 2020-03-18 |
| CN109069607A (zh) | 2018-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018016912A2 (pt) | novo antígeno para uso na vacina contra malária | |
| BR112017014219A2 (pt) | vacinas à base de nanopartículas multivalentes | |
| BR112019010275A2 (pt) | adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano | |
| BR112018017307A2 (pt) | molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus | |
| BR112017006178A2 (pt) | região fc, anticorpos, formulação farmacêutica e usos dos anticorpos | |
| BR112018011122A2 (pt) | antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos | |
| BR112017009807A2 (pt) | métodos e formulações para tratamento de doenças oculares vasculares | |
| BR112017017949A2 (pt) | regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna | |
| BR112016015422A2 (pt) | formulações de vacina de frasco único | |
| BR112014020019A8 (pt) | vetores poxvirais recombinantes expressando tanto proteínas da raiva e ox40 e vacinas feitas a partir destes | |
| BR112015023105A2 (pt) | construto de imunógeno de peptídeo a?, composições, anticorpo e usos de um construto ou combinação de imunógeno de peptídeo a? | |
| AR089797A1 (es) | Vacunas contra clostridum difficile que comprenden toxinas recombinantes | |
| BR112016006122A2 (pt) | composições imunogênicas e métodos com coronavírus da síndrome respiratória do oriente médio (mers-cov) | |
| BR112016020368A2 (pt) | proteínas fc multiméricas | |
| BR112013032251A2 (pt) | composição estável da vacina da cepa do vírus chikungunya inativado com uma ou mais mutações; método para induzir uma resposta imune protetora em indivíduos humanos contra infecções causadas pelo vírus chikungunya; uso de isolados do vírus chikungunya; composição combinada da vacina | |
| BR112013009649A2 (pt) | composição imunogênica, métodos para provocar uma resposta imune protetora em um paciente humano e para fornecer proteção imune em seres humanos contra doença, e, uso de uma composição | |
| EP4272750A3 (en) | Protein antigens that provide protection against pneumococcal colonization and/or disease | |
| CL2016000538A1 (es) | Compuesto que comprende la proteína globo h y klh, composiciones de una vacuna de hidratos de carbono para la inducción de respuestas inmunes y usos de los mismos | |
| BR112015030229A8 (pt) | Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado | |
| BR112016004108A2 (pt) | métodos para expressar uma molécula antigênica ou uma parte da mesma e para geração de uma resposta imune, composição farmacêutica, célula ou população de células, usos de uma população de células e de uma molécula antigênica, moléculas antigênica, agentes de fotossensibilização e ligante tlr e agente, produto, e, kit | |
| BR112014023414A2 (pt) | vacina de herpesvirus-1 equino recombinante contendo uma glicoproteína c mutante e seus usos | |
| BR112015028499A2 (pt) | Peptídeo para induzir apoptose específica de mastócito e uso do mesmo | |
| BR112015023886A2 (pt) | polipeptídeo, ácido nucleico, composição farmacêutica, e, método | |
| BR112015019283A2 (pt) | composições e métodos de aprimoramento de respostas imunes à eiméria ou infecção por eiméria limitadora | |
| BR112016006210A2 (pt) | terapia e vacina contra gripe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |